Omega 3 fatty acids for prevention and treatment of cardiovascular disease
Open accessAbstract
BACKGROUND: It has been suggested that omega 3 (W3, n-3 or omega-3) fats from oily fish and plants are beneficial to health. OBJECTIVES: To assess whether dietary or supplemental omega 3 fatty acids alter total mortality, cardiovascular events or cancers using both RCT and cohort studies. SEARCH STRATEGY: Five databases including CENTRAL, MEDLINE and EMBASE were searched to February 2002. No language restrictions were applied. Bibliographies were checked and authors contacted. SELECTION CRITERIA: RCTs were included where omega 3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months. Cohorts were included where a cohort was followed up for at least six months and omega 3 intake estimated. DATA COLLECTION AND ANALYSIS: Studies were assessed for inclusion, data extracted and quality assessed independently in duplicate. Random effects meta-analysis was performed separately for RCT and cohort data. MAIN RESULTS: Forty eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in those taking additional omega 3 fats (with significant statistical heterogeneity). Sensitivity analysis, retaining only studies at low risk of bias, reduced heterogeneity and again suggested no significant effect of omega 3 fats. Restricting analysis to trials increasing fish-based omega 3 fats, or those increasing short chain omega 3s, did not suggest significant effects on mortality or cardiovascular events in either group. Subgroup analysis by dietary advice or supplementation, baseline risk of CVD or omega 3 dose suggested no clear effects of these factors on primary outcomes. Neither RCTs nor cohorts suggested increased relative risk of cancers with higher omega 3 intake but estimates were imprecise so a clinically important effect could not be excluded. REVIEWERS' CONCLUSIONS: It is not clear that dietary or supplemental omega 3 fats alter total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population. There is no evidence we should advise people to stop taking rich sources of omega 3 fats, but further high quality trials are needed to confirm suggestions of a protective effect of omega 3 fats on cardiovascular health. There is no clear evidence that omega 3 fats differ in effectiveness according to fish or plant sources, dietary or supplemental sources, dose or presence of placebo.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Randomized clinical trials of fish oil supplements have shown mixed effects on CHD events.
“randomized clinical trials using fish oil supplements have found mixed effects on CHD events.2–8”
From ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies (2016) · cites this paper as [3]
In those trials, background dietary intake was usually not measured, and many participants may have already had adequate intake from diet.
“the background dietary intake in these trials was not usually measured, and many participants may have had adequate intake from diet alone.”
From ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies (2016) · cites this paper as [3]
Most of those trials gave supplements for a few years or less and enrolled patients with existing CHD or at high CHD risk who were taking multiple cardiovascular drugs.
“most trials provided supplements for a few years or less and were conducted in patients with preexisting CHD or at high risk for CHD and taking multiple cardiovascular drugs.”
From ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies (2016) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 407 · Cited by 264
- Authors
- Hooper, L., Harrison, R. A., Summerbell, C. D., Moore, H., Worthington, H. V., Ness, A., Capps, N., Davey Smith, G., Riemersma, R., & Ebrahim, S.
- Affiliations
- University of East Anglia (GB)
- University of Manchester; Division of Epidemiology and Health Sciences; Oxford Road Manchester UK M13 9PT
- Teesside University (GB)
- University of Manchester (GB)
- Department of Social Medicine; Canynge Hall Whiteladies Road Bristol Avon UK BS8 2PR
- Royal Princess Hospital NHS Trust; Department of Clinical Biochemistry; Apley Castle Telford UK TF6 6TF
- University of Bristol; Department of Social Medicine; Canynge Hall Whiteladies Road Bristol UK BS8 2PR
- University of Edinburgh (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2004-10-18
- Issue
- 4
- Pages
- CD003177-CD003177
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC4170890
- OpenAlex
- W1895646380
- Cited by
- 264
- References
- 407
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 6 · 2018: 9 · 2017: 9 · 2016: 10 · 2015: 20 · 2014: 21 · 2013: 22 · 2012: 21
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Update notices
- new_version (2018-07-18)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- omega-3 fatty acids, cardiovascular disease, dietary supplementation, fish oil, all-cause mortality, cardiovascular events, cancer risk, dietary recommendations
- MeSH terms
- Cardiovascular Diseases, Humans, Fatty Acids, Omega-3, Randomized Controlled Trials as Topic, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review